Stockscreener 앱 받기
1.09
10.10%
0.10
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan
HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World
Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network
Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan
PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan
PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire
Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan
Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire
Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Contrasting Plus Therapeutics (NASDAQ:PSTV) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) - Defense World
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus: Q3 Earnings Snapshot - New Haven Register
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Advances Cancer Drug Pipeline, Reports $4.4M Grant Revenue in Q3 | PSTV Stock News - StockTitan
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
2.88%
2.65%
자본화:
|
볼륨(24시간):